Its other major products include Botox ($5 billion in 2022 revenues), Imbruvica to treat cancer ($4.5 billion in 2022 revenues), Rinvoq to treat arthritis ($2.5 billion in 2022 revenues), Venclexta to treat leukemia and lymphoma ($2 billion in annual revenues), Vraylar to treat schizophrenia and bipolar disorder ($2 billion in 2022 revenues), and Mavyret to treat Hepatitis C ($1.5 billion in 2022 revenues).

AbbVie products include a wide range of drugs. Some of the more well-known AbbVie drugs are: Celexa — a treatment for depression. Lexapro — a treatment for depression and anxiety. Loestrin — a low-dose birth control pill. Norco — a hydrocodone and acetaminophen medication used to treat moderate pain.